4586 Medrx Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4586

TSE Growth

Medrx Co.,Ltd.

108

JPY

(+1.89%)

Mar 13, 3:30 pm JST

0.67

USD

Mar 13, 2:30 am EDT

Result

ー

PTS

outside of trading hours

106.1

Mar 13, 11:58 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	59	-1,098	-1,112	-1,111	-43.8	0	Feb 10, 2023	J-GAAP
Dec, 2023	29	-933	-930	-932	-26.8	0	Feb 9, 2024	J-GAAP
Dec, 2024	257	-793	-755	-806	-18.6	0	Feb 14, 2025	J-GAAP
Dec, 2025	128	-941	-937	-937	-17.4	0	Feb 13, 2026	J-GAAP
Dec, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 13, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 10, 2021	327	-886	-890	-892	0	J-GAAP
	May 18, 2021	327	-1,111	-1,115	-1,117	0	J-GAAP
	Nov 12, 2021	328	-766	-778	-781	0	J-GAAP
	Nov 19, 2021	228	-866	-878	-881	0	J-GAAP
	Dec 27, 2021	8	-1,086	-1,098	-1,101	0	J-GAAP
Results	Feb 10, 2022	8	-1,061	-1,066	-1,059	0	J-GAAP
Dec, 2022	Feb 10, 2022	Available in future release
	Nov 11, 2022
	Dec 27, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Sep 15, 2023
	Sep 29, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	Apr 24, 2024
	Jul 12, 2024
	Aug 9, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025
Results	Feb 13, 2026
Dec, 2026	Feb 13, 2026	ー	ー	ー	ー	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2007	278	－	Available in future release
Dec, 2008	124	-55.4
Dec, 2009	547	+341.1
Dec, 2010	291	-46.8
Dec, 2011	741	+154.6
Dec, 2012	87	-88.3
Dec, 2013	68	-21.8
Dec, 2014	26	-61.8
Dec, 2015	37	+42.3
Dec, 2016	22	-40.5
Dec, 2017	198	+800.0
Dec, 2018	8	-96.0
Dec, 2019	169	+2,012.5
Dec, 2020	115	-32.0
Dec, 2021	8	-93.0
Dec, 2022	59	+637.5
Dec, 2023	29	-50.8
Dec, 2024	257	+786.2
Dec, 2025	128	-50.2
Dec, 2026 Guidance	ー	-100.0	ー	+100.0	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	257	-793	-309	-40.58	-37.25	0.12	-18.6
Dec, 2025	128	-941	-735	-45.67	-42.28	0.06	-17.4
Dec, 2026 Guidance	ー	ー	ー	ー	ー	ー	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	741	-434	-147	-166	-17.4
Fiscal Year	Dec, 2011	Dec, 2011	Dec, 2009	Dec, 2009	Dec, 2025

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	6	-478	-480	-481	-15.0	0	Aug 10, 2023	J-GAAP
Jan - Jun, 2024	231	-135	-84	-61	-1.5	0	Aug 9, 2024	J-GAAP
Jan - Jun, 2025	18	-609	-623	-629	-12.8	0	Aug 8, 2025	J-GAAP
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 13, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 10, 2023	27	-488	-494	-495	0	J-GAAP
Results	Aug 10, 2023	6	-478	-480	-481	0	J-GAAP
Jun, 2024	Feb 9, 2024	Available in future release
	Apr 24, 2024
	May 10, 2024
Results	Aug 9, 2024
Jun, 2025	Feb 14, 2025
Results	Aug 8, 2025
Jun, 2026	Feb 13, 2026	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	-933	-913	-913	0	1,639	1,720	83.82	J-GAAP
Dec, 2024	-793	-806	-803	-3	1,066	1,977	86.90	J-GAAP
Dec, 2025	-941	-970	-888	-82	745	1,754	81.32	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	29	-933	-930	-932	-26.8	0	Feb 9, 2024	J-GAAP
Dec, 2024	257	-793	-755	-806	-18.6	0	Feb 14, 2025	J-GAAP
Dec, 2025	128	-941	-937	-937	-17.4	0	Feb 13, 2026	J-GAAP
YoY	-50.2%	-18.7%	-24.1%	-16.3%	+6.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	0	-176	-127	-128	-3.3	-Inf	May 10, 2024	J-GAAP
Apr - Jun, 2024	231	41	43	67	1.7	17.7	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	24	-244	-259	-259	-6.2	-1,016.7	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	2	-414	-412	-486	-11.2	-20,700.0	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	2	-419	-422	-429	-9.0	-20,950.0	May 9, 2025	J-GAAP
Apr - Jun, 2025	16	-190	-201	-200	-4.1	-1,187.5	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	100	-133	-134	-140	-2.7	-133.0	Nov 14, 2025	J-GAAP
Oct - Dec, 2025	10	-199	-180	-168	-3.1	-1,990.0	Feb 13, 2026	J-GAAP
YoY	+400.0%	+51.9%	+56.3%	+65.4%	+72.0%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	7	－	Available in future release
Apr - Jun, 2021	0	-100.0
Jul - Sep, 2021	1	－
Oct - Dec, 2021	0	-100.0
Jan - Mar, 2022	1	-85.7
Apr - Jun, 2022	8	－
Jul - Sep, 2022	0	-100.0
Oct - Dec, 2022	50	－
Jan - Mar, 2023	6	+500.0
Apr - Jun, 2023	0	-100.0
Jul - Sep, 2023	23	－
Oct - Dec, 2023	0	-100.0
Jan - Mar, 2024	0	-100.0
Apr - Jun, 2024	231	－
Jul - Sep, 2024	24	+4.3
Oct - Dec, 2024	2	－
Jan - Mar, 2025	2	－
Apr - Jun, 2025	16	-93.1
Jul - Sep, 2025	100	+316.7
Oct - Dec, 2025	10	+400.0	-199	+51.9	-180	+56.3	-3.1	+72.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	231	41	43	67	1.7
Fiscal Year	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2023	48.44	90.5	2,052	1,858	-915	ー	Feb 9, 2024	J-GAAP
Dec, 2024	44.53	92.9	2,275	2,114	-787	ー	Feb 14, 2025	J-GAAP
Dec, 2025	33.51	92.2	2,157	1,989	-898	ー	Feb 13, 2026	J-GAAP

Medrx Co.,Ltd.(4586) Financial Results